|
|
|
Volumn 6, Issue 3, 2004, Pages 344-349
|
|
Technology evaluation: rh lactoferrin, Agennix
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ACETYLSALICYLIC ACID;
ANTINEOPLASTIC AGENT;
BECAPLERMIN;
CISPLATIN;
GLYCOPROTEIN;
IMMUNOMODULATING AGENT;
INDOMETACIN;
LACTOFERRIN;
NONSTEROID ANTIINFLAMMATORY AGENT;
PLACEBO;
RECOMBINANT PROTEIN;
ANTIINFLAMMATORY ACTIVITY;
ANTIMICROBIAL ACTIVITY;
ASTHMA;
CANCER;
CHRONIC DISEASE;
CLINICAL TRIAL;
DOSE RESPONSE;
DRUG BIOAVAILABILITY;
DRUG BLOOD LEVEL;
DRUG EFFICACY;
DRUG INDICATION;
DRUG METABOLISM;
DRUG POTENTIATION;
DRUG RESEARCH;
DRUG SAFETY;
DRUG SYNTHESIS;
DRUG TOLERABILITY;
ENTEROPATHY;
GEL;
HUMAN;
IMMUNOMODULATION;
NONHUMAN;
PROTEIN FUNCTION;
SHORT SURVEY;
SIDE EFFECT;
SOLID TUMOR;
STRUCTURE ACTIVITY RELATION;
TOXICITY TESTING;
WOUND;
ASPERGILLUS;
ASTHMA;
CLINICAL TRIALS, PHASE I;
CLINICAL TRIALS, PHASE II;
HUMANS;
LACTOFERRIN;
NEOPLASMS;
RECOMBINANT PROTEINS;
WOUND HEALING;
WOUNDS AND INJURIES;
|
|
EID: 3242882586
PISSN: 14648431
EISSN: None
Source Type: Journal
DOI: None Document Type: Short Survey |
|
Times cited : (14)
|
|
References (0)
|
